Search

Displaying results 1941 - 1950 of 10000 in total
  1. Drug

    Luspatercept

    go.drugbank.com/drugs/DB12281
    ApprovedInvestigational

    [A187835] Luspatercept's novel mechanism of action, then, is uniquely suited for the treatment of conditions in which late-stage erythropoiesis is defective, such as beta thalassemia and other myelodysplastic … [L42455] Luspatercept is novel in that it ameliorates anemia via action on late-stage erythropoiesis, in contrast to typical erythropoiesis-stimulating agents (ESAs), such as [darbepoetin alfa] and [epoetin

  2. Drug

    Nitazoxanide

    go.drugbank.com/drugs/DB00507
    ApprovedInvestigationalVet approved

    Nitazoxanide belongs to the class of drugs known as _thiazolides_. … This drug is effective in the treatment of gastrointestinal infections including Cryptosporidium parvum or Giardia lamblia in healthy subjects. It is generally well tolerated.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  3. Drug

    Thenalidine

    go.drugbank.com/drugs/DB04826
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1963 due to concerns involving neutropenia.

    Categories: Antihistamines for Systemic Use, Antihistamines for Topical Use
  4. Drug

    Tetrofosmin

    go.drugbank.com/drugs/DB11180
    Approved

    Tetrofosmin is part of the group of diphosphines. Tetrofosmin is used in conjunction with technetium Tc-99m as a radiopharmaceutical.[A7788]

  5. Drug

    Phenyltoloxamine

    go.drugbank.com/drugs/DB11160
    Approved

    It is available in combination products that also contain other analgesics and antitussives such as acetaminophen. … Phenyltoloxamine is an antihistamine drug with sedative and analgesic effects. It is a H1 receptor blocker and a member of the ethanolamine class of antihistaminergic drugs.

  6. Drug

    Ensitrelvir

    go.drugbank.com/drugs/DB18834
    ApprovedInvestigational

    Ensitrelvir is under investigation in clinical trial NCT05605093 (Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)).

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseSynonyms: S-217622
  7. Drug

    Octreotide

    go.drugbank.com/drugs/DB00104
    ApprovedInvestigational

    Acromegaly is a life-threatening disease requiring life-long management. … Acromegaly is a disorder caused by excess growth hormone (GH), increasing the growth of body tissues and causing metabolic dysfunction.

    Categories: Sex Hormones and Insulins
  8. Drug

    Talquetamab

    go.drugbank.com/drugs/DB16678
    ApprovedInvestigational

    Talquetamab is a IgG4-PAA bispecific G protein-coupled receptor class C group 5 member D (GPRC5D)-directed CD3 T-cell engager. … [A260890] The Committee for Medicinal Products for Human Use (CHMP) of the EMA recommended conditional marketing authorization for talquetamab for the treatment of relapsed or refractory multiple myeloma

  9. Drug

    Relatlimab

    go.drugbank.com/drugs/DB14851
    ApprovedInvestigational

    [L41265,L41300] It was the first anti-LAG-3 antibody to demonstrate benefit in a Phase 3 study, as well as the first to receive FDA approval. … Relatlimab is a human IgG4 monoclonal antibody and novel immune checkpoint inhibitor that targets lymphocyte activation gene-3 (LAG-3).

  10. Drug

    Bufexamac

    go.drugbank.com/drugs/DB13346
    ApprovedWithdrawn

    It is typically administered topically for the treatment of subacute and chronic eczema of the skin, including atopic eczema and other inflammatory dermatoses, as well as sunburn and other minor burns, … The use of bufexamac has been discontinued in Canada and the United States, which may be due to undetermined clinical efficacy and a high prevalence of contact sensitization [A32822].

    Categories: Antiinflammatory Preparations, Non-Steroids for Topical Use